Cyberounds Logo
September 27, 2020 | LOGIN | REGISTER | HELP | 

email a friend print Bookmark and Share
The Management of Major Depression During Pregnancy
CME credit is no longer available for this conference.
Jennifer L. Payne, M.D.

Dr. Payne is Associate Professor of Psychiatry and Director, Women's Mood Disorders Center, Johns Hopkins School of Medicine, Baltimore, MD.

Within the past 12 months, Dr. Payne has been a consultant to AstraZeneca and Pfizer.

Off-label uses of medications will be discussed throughout this Cyberounds.

Release Date: 07/01/2012
Termination Date: 07/01/2015

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • List two known risks to the baby of not treating a major depressive episode during pregnancy
  • Identify two potential risks to the baby of the use of serotonin reuptake inhibitors during the third trimester
  • Apply the risk factors that should be taken into account when deciding on a clinical plan for the management of major depression during pregnancy.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Please click below to accept the terms of this CME activity